<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3990">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01304277</url>
  </required_header>
  <id_info>
    <org_study_id>HGT-REP-082</org_study_id>
    <nct_id>NCT01304277</nct_id>
  </id_info>
  <brief_title>This Study is Designed to Evaluate PD/PK and Safety of Replagal Manufactured by Two Different Processes.</brief_title>
  <official_title>A Phase II Comparability Study Between Replagal® Produced From Agalsidase Alfa Manufactured by 2 Different Processes in Adult Male Patients With Fabry Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate safety and PK/PD in Canadian Fabry patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In 2008, a change in the agalsidase alfa drug substance manufacturing process was made.
      There are no changes to the drug product formulation, manufacturing site, manufacturing
      process, or container closure.

      An agalsidase alfa bioreactor manufacturing process (agalAF1) utilizing animal
      component-free media replaced the previous roller bottle (RB) process.

      This study is designed to provide PD/PK and safety data. The assessment schedule is designed
      to capture the PK profile of drug uptake in the blood as well the pharmacologic effect which
      manifests over the course of weeks. Each patient will serve as his own control.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Change From Baseline to Week 16 (EOS) in Urine Gb3 Levels</measure>
    <time_frame>Baseline to EOS</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 16 (EOS) in Plasma Gb3 Levels</measure>
    <time_frame>Baseline to EOS</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-normalized Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Sample (AUClast/Dose)</measure>
    <time_frame>Week 0 to Week 14</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-normalized AUC Extrapolated to Infinity (AUC∞/Dose)</measure>
    <time_frame>Week 0 to Week 14</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-normalized Maximum Serum Concentration (Cmax/Dose)</measure>
    <time_frame>Week 0 to Week 14</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Assess Safety and Tolerability by Anti-agalsidase Alfa Antibody Status (in Serum) at End of Study</measure>
    <time_frame>EOS</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Summary of TEAEs by Treatment (Replagal RB and Replagal AF)</measure>
    <time_frame>Week 2 to EOS</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To Assess Safety and Tolerability by Anti-agalsidase Alfa Antibody Status, concomitant medication, vital signs and ECG.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Fabry Disease</condition>
  <arm_group>
    <arm_group_label>Replagal® (0.2 mg/kg, IV, EOW)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Screening period of approximately 14 days during which all patients received 1 infusion of 0.2 mg/kg Replagal RB (Week 0)
Treatment period of 14 weeks during which all patients received 7 infusions of 0.2 mg/kg Replagal AF</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>agalsidase alfa</intervention_name>
    <arm_group_label>Replagal® (0.2 mg/kg, IV, EOW)</arm_group_label>
    <other_name>Replagal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patient must be diagnosed with Fabry disease using the following criteria: The
             patient is a hemizygous male with Fabry disease as confirmed by a deficiency of
             α-galactosidase A activity measured in serum, leukocytes, or fibroblasts or has a
             confirmed mutation of the α-galactosidase A gene.

          2. Patient is male and between 18 and 65 years of age, inclusive.

          3. Patient must be willing to remain in the clinic as required by the study and comply
             with the procedures and evaluations of the study.

          4. At the time of confirmation of study eligibility visit, patients must have received
             at least 26 weeks of treatment with RB Replagal at a dose of 0.2 mg/kg administered
             IV EOW.

          5. Patient provides informed consent.

        Patients who are naive to ERT:

        1. Treatment naive patients must have a pretreatment plasma Gb3 level above the normal
        range (if value is available).

        Exclusion Criteria:

          1. Patient is unable to be venipunctured and/or tolerate venous access.

          2. Patient has tested positive for anti-agalsidase alfa antibodies either at screening
             or confirmation of eligibility visit.

          3. Patient had pre-ERT plasma Gb3 levels within the normal range (if value is
             available).

          4. Patient is participating in any other Shire HGT investigational study.

          5. Patient is currently on dialysis, is expected to begin dialysis during the study, has
             received a kidney transplant, or is on the renal transplant waiting list.

          6. Patient is unable to comply with the protocol (eg, clinical relevant medical
             condition making implementation of the protocol difficult, unstable social situation,
             or otherwise unlikely to complete the study) or is, in the opinion of the
             Investigator, otherwise unsuited for the study.

          7. The patient is enrolled in another clinical study that involves clinical
             investigations or use of any investigational product (drug or device), except for the
             Canadian Fabry Disease Initiative, within 6 months prior to receiving the first dose
             of AF Replagal in this study or at any time during the study.

          8. The patient has previously received AF Replagal prior to study entry.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Wijatyk, MD</last_name>
    <role>Study Director</role>
    <affiliation>Shire Human Genetic Therapies, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2H7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INC Research</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5V 2T3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital du Sacre-Coeur de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 25, 2014</lastchanged_date>
  <firstreceived_date>February 15, 2011</firstreceived_date>
  <firstreceived_results_date>December 30, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Replagal</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first patient participated in the study on 06 December 2011 and the last patient completed the study procedures on 28 December 2012.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Replagal® (0.2 mg/kg, EOW)</title>
          <description>Patients who had received Replagal RB for at least 26 weeks prior to entering the study REP-082, received 1 dose of Replagal RB at baseline before switching to Replagal AF. They then received 14 weeks of treatment with Replagal AF.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Screening (Replagal RB, Week 0- Week 2)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment (Replagal AF, Week 2- EOS)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Replagal® (0.2 mg/kg, EOW)</title>
          <description>Patients who had received Replagal RB for at least 26 weeks prior to entering the study REP-082, received 1 dose of Replagal RB at baseline before switching to Replagal AF. They then received 14 weeks of treatment with Replagal AF.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="39.8" spread="13.589"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>CANADA</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Study Specific Characteristic [Urine Gb3]</title>
          <description>Baseline is the average of Gb3 (globotriaosylceramide) levels on RB Replagal at screening, Week 0, and Week 2 prior to AF Replagal dosing.</description>
          <units>nmol/g creatinine</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="919.27" spread="990.144"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Study Specific Characteristic [Plasma Gb3]</title>
          <description>Baseline is the average of Gb3 (globotriaosylceramide) levels on RB Replagal at screening, Week 0, and Week 2 prior to AF Replagal dosing.</description>
          <units>nmol/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="5.276" spread="1.562"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 16 (EOS) in Urine Gb3 Levels</title>
        <time_frame>Baseline to EOS</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Replagal® (0.2 mg/kg, EOW)</title>
            <description>Patients who had received Replagal RB for at least 26 weeks prior to entering the study REP-082, received 1 dose of Replagal RB at baseline before switching to Replagal AF. They then received 14 weeks of treatment with Replagal AF.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline to Week 16 (EOS) in Urine Gb3 Levels</title>
            <units>(nmol/g creatinine)</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-28.68" spread="192.659"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 16 (EOS) in Plasma Gb3 Levels</title>
        <time_frame>Baseline to EOS</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Replagal® (0.2 mg/kg, EOW)</title>
            <description>Patients who had received Replagal RB for at least 26 weeks prior to entering the study REP-082, received 1 dose of Replagal RB at baseline before switching to Replagal AF. They then received 14 weeks of treatment with Replagal AF.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline to Week 16 (EOS) in Plasma Gb3 Levels</title>
            <units>(nmol/mL)</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.170" spread="0.503"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose-normalized Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Sample (AUClast/Dose)</title>
        <time_frame>Week 0 to Week 14</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Replagal® (0.2 mg/kg, EOW)</title>
            <description>Patients who had received Replagal RB for at least 26 weeks prior to entering the study REP-082, received 1 dose of Replagal RB at baseline before switching to Replagal AF. They then received 14 weeks of treatment with Replagal AF.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Dose-normalized Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Sample (AUClast/Dose)</title>
            <units>Ratio</units>
            <param>Geometric Mean</param>
            <dispersion>90% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Week 14 versus 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.65" lower_limit="0.61" upper_limit="0.72"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 14 versus 2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.05" lower_limit="0.94" upper_limit="1.23"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose-normalized AUC Extrapolated to Infinity (AUC∞/Dose)</title>
        <time_frame>Week 0 to Week 14</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Replagal® (0.2 mg/kg, EOW)</title>
            <description>Patients who had received Replagal RB for at least 26 weeks prior to entering the study REP-082, received 1 dose of Replagal RB at baseline before switching to Replagal AF. They then received 14 weeks of treatment with Replagal AF.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Dose-normalized AUC Extrapolated to Infinity (AUC∞/Dose)</title>
            <units>Ratio</units>
            <param>Geometric Mean</param>
            <dispersion>90% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Week 14 versus 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.67" lower_limit="0.62" upper_limit="0.75"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 14 versus 2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.07" lower_limit="0.97" upper_limit="1.26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose-normalized Maximum Serum Concentration (Cmax/Dose)</title>
        <time_frame>Week 0 to Week 14</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Replagal® (0.2 mg/kg, EOW)</title>
            <description>Patients who had received Replagal RB for at least 26 weeks prior to entering the study REP-082, received 1 dose of Replagal RB at baseline before switching to Replagal AF. They then received 14 weeks of treatment with Replagal AF.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Dose-normalized Maximum Serum Concentration (Cmax/Dose)</title>
            <units>Ratio</units>
            <param>Geometric Mean</param>
            <dispersion>90% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Week 14 versus 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.81" lower_limit="0.76" upper_limit="0.91"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 14 versus 2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.05" lower_limit="0.96" upper_limit="1.21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Assess Safety and Tolerability by Anti-agalsidase Alfa Antibody Status (in Serum) at End of Study</title>
        <time_frame>EOS</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Replagal® (0.2 mg/kg, EOW)</title>
            <description>Patients who had received Replagal RB for at least 26 weeks prior to entering the study REP-082, received 1 dose of Replagal RB at baseline before switching to Replagal AF. They then received 14 weeks of treatment with Replagal AF.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>To Assess Safety and Tolerability by Anti-agalsidase Alfa Antibody Status (in Serum) at End of Study</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Anti-Agalsidase alfa Antibody Negative</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-Agalsidase alfa Antibody Positive (IgG)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-Agalsidase alfa Antibody Positive (IgM)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Summary of TEAEs by Treatment (Replagal RB and Replagal AF)</title>
        <description>To Assess Safety and Tolerability by Anti-agalsidase Alfa Antibody Status, concomitant medication, vital signs and ECG.</description>
        <time_frame>Week 2 to EOS</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Replagal RB</title>
            <description>Patients who had received Replagal RB for at least 26 weeks prior to entering the study REP-082.</description>
          </group>
          <group group_id="O2">
            <title>Replagal AF</title>
            <description>Patients received 7 EOW infusions of treatment with Replagal AF from week 2 to week 14 in REP-082.</description>
          </group>
          <group group_id="O3">
            <title>Overall</title>
            <description>Overall number of patients who experienced adverse events during the course of REP-082 study.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="17"/>
                  <measurement group_id="O3" value="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Overall Summary of TEAEs by Treatment (Replagal RB and Replagal AF)</title>
            <description>To Assess Safety and Tolerability by Anti-agalsidase Alfa Antibody Status, concomitant medication, vital signs and ECG.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>No TEAE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Experienced at least one TEAE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="12"/>
                  <measurement group_id="O3" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Deaths</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Discontinued due to a TEAE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Experienced at least one drug-related TEAE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Experienced at least one SAE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>At least one severe or life- threatening TEAE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>At least one IRR (infusion related reaction)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to EOS</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Replagal® (0.2 mg/kg, IV, EOW)</title>
          <description>Overall patients that participated in REP-082</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Sensation of heaviness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Shire’s agreements with investigators vary. All agreements provide Shire the right to embargo communications regarding trial results prior to public release for a period ≤180 days from the time submitted to Shire for review. Shire does not prohibit publication, but can require the removal of confidential information (excluding trial results) and can request postponement of a single-center publication until after disclosure of the trial’s multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Physician</name_or_title>
      <organization>Shire Development LLC</organization>
      <phone>+1 866 842 5335</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
